116 related articles for article (PubMed ID: 3864520)
1. Dosage predictions in high-dose methotrexate infusions. Part 1: Evaluation of the classic test-dose protocol.
Cano JP; Bruno R; Lena N; Favre R; Iliadis A; Imbert AM
Cancer Drug Deliv; 1985; 2(4):271-6. PubMed ID: 3864520
[TBL] [Abstract][Full Text] [Related]
2. Dosage predictions in high-dose methotrexate infusions. Part 2: Bayesian estimation of methotrexate clearance.
Bruno R; Iliadis A; Favre R; Lena N; Imbert AM; Cano JP
Cancer Drug Deliv; 1985; 2(4):277-83. PubMed ID: 4063950
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate test-dose protocol in the presence of 7-hydroxy-methotrexate.
Lena N; Imbert AM; Favre R; Cano JP; Carcassonne Y
Eur J Cancer Clin Oncol; 1987 May; 23(5):481-5. PubMed ID: 3477455
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate-vindesine association in the treatment of head and neck cancer influence of vindesine on methotrexate's pharmacokinetic behavior.
Lena N; Imbert AM; Pignon T; Favre R; Meyer G; Cano JP; Carcassonne Y
Cancer Chemother Pharmacol; 1984; 12(2):120-4. PubMed ID: 6697425
[TBL] [Abstract][Full Text] [Related]
5. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.
Monjanel S; Rigault JP; Cano JP; Carcassonne Y; Favre R
Cancer Chemother Pharmacol; 1979; 3(3):189-96. PubMed ID: 527209
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.
Luyckx M; Cazin JL; Brunet C; Gosselin P; Demaille MC
Eur J Clin Pharmacol; 1985; 28(4):457-62. PubMed ID: 3839754
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions.
Parker RI; Forman EN; Krumm KF; Abeel MJ; Martin HF
Ther Drug Monit; 1986; 8(4):393-9. PubMed ID: 3469802
[TBL] [Abstract][Full Text] [Related]
10. Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion.
Wang YM; Kim PY; Lantin E; van Eys DC; Romsdahl MM; Sutow WW
Med Pediatr Oncol; 1978; 4(3):221-9. PubMed ID: 308151
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy.
Dupuis C; Mercier C; Yang C; Monjanel-Mouterde S; Ciccolini J; Fanciullino R; Pourroy B; Deville JL; Duffaud F; Bagarry-Liegey D; Durand A; Iliadis A; Favre R
Anticancer Drugs; 2008 Mar; 19(3):267-73. PubMed ID: 18510172
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits.
Iven H; Brasch H; Engster J
Cancer Chemother Pharmacol; 1985; 15(2):115-20. PubMed ID: 4017160
[TBL] [Abstract][Full Text] [Related]
13. [Bolus and maintenance infusion of high-dose methotrexate].
Amino K; Kawaguchi N; Matsumoto S; Manabe J; Tabata D; Machida M
Gan To Kagaku Ryoho; 1989 May; 16(5):2045-9. PubMed ID: 2730094
[TBL] [Abstract][Full Text] [Related]
14. Test dose for predicting high-dose methotrexate infusions.
Kerr IG; Jolivet J; Collins JM; Drake JC; Chabner BA
Clin Pharmacol Ther; 1983 Jan; 33(1):44-51. PubMed ID: 6848298
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics of methotrexate and therapeutic drug monitoring in children with osteosarcoma. Computer simulation using a pharmacokinetic model].
Piekarczyk A; Zimak J; TaljaĊski W
Med Wieku Rozwoj; 2000; 4(2 Suppl 2):27-33. PubMed ID: 11178326
[TBL] [Abstract][Full Text] [Related]
16. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.
Wang YM; Sutow WW; Romsdahl MM; Perez C
Cancer Treat Rep; 1979 Mar; 63(3):405-10. PubMed ID: 284845
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma.
Fujita Y; Nakamura T; Aomori T; Nishiba H; Shinozaki H; Yanagawa T; Takagishi K; Watanabe H; Okada Y; Nakamura K; Horiuchi R; Yamamoto K
J Chemother; 2010 Jun; 22(3):186-90. PubMed ID: 20566424
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.
Erttmann R; Bielack S; Landbeck G
Cancer Chemother Pharmacol; 1985; 15(2):101-4. PubMed ID: 3874719
[TBL] [Abstract][Full Text] [Related]
19. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and clinical studies of 24-h infusions of high-dose methotrexate.
Cohen HJ; Jaffe N
Cancer Chemother Pharmacol; 1978; 1(1):61-4. PubMed ID: 373909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
